Biosimilars: An Overview for Clinicians

In this educational activity experts in oncology and immunology answer your most frequently asked questions about biosimilars including:
-How biosimilars differ from their reference biologic and small molecule generics
-Safety efficacy and regulatory approval pathways
-Potential role in oncology and immunology

Share

Program Content

Activities

Downloadable Slideset
Expert Answers to Frequently Asked Questions About Biosimilars
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 09, 2017

Expires: March 08, 2018

Activities

Patients and Biosimilars
Helping Patients Accept Biosimilars in Oncology Practice
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 01, 2017

Expires: April 30, 2018

Faculty

cover img faculity

Sanjiv S. Agarwala, MD

Chief, Medical Oncology & Hematology
St Luke s Cancer Center
Bethlehem, Pennsylvania

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.